Merck & Company Inc (MRK)vsViking Holdings Ltd (VIK)
MRK
Merck & Company Inc
$119.63
+0.59%
HEALTHCARE · Cap: $295.77B
VIK
Viking Holdings Ltd
$68.58
-4.20%
CONSUMER CYCLICAL · Cap: $32.40B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 900% more annual revenue ($65.01B vs $6.50B). MRK leads profitability with a 28.1% profit margin vs 17.6%. MRK trades at a lower P/E of 16.4x. VIK earns a higher WallStSmart Score of 66/100 (B-).
MRK
Buy59
out of 100
Grade: C
VIK
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-141.3%
Fair Value
$49.57
Current Price
$119.63
$70.06 premium
Margin of Safety
+36.3%
Fair Value
$120.28
Current Price
$68.58
$51.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Strong operational efficiency at 20.9%
Revenue surging 27.8% year-over-year
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Moderate valuation
2.3% earnings growth
ROE of 2.5% — below average capital efficiency
Trading at 28.0x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : VIK
The strongest argument for VIK centers on Operating Margin, Revenue Growth. Profitability is solid with margins at 17.6% and operating margin at 20.9%. Revenue growth of 27.8% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : VIK
The primary concerns for VIK are P/E Ratio, EPS Growth, Return on Equity.
Key Dynamics to Monitor
MRK profiles as a value stock while VIK is a growth play — different risk/reward profiles.
VIK is growing revenue faster at 27.8% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VIK scores higher overall (66/100 vs 59/100), backed by strong 17.6% margins and 27.8% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Viking Holdings Ltd
CONSUMER CYCLICAL · TRAVEL SERVICES · USA
Viking Holdings Ltd engages in the passenger shipping and other forms of passenger transport in North America, the United Kingdom, and internationally. The company is headquartered in Pembroke, Bermuda.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?